Overview

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH)
Phase:
Phase 2
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.
Treatments:
Seladelpar